CompletedNCT01162746
Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration
PHASE2 · 40 planned enrolment
- Countries listed
- 1
- Registry update
- May 25, 2017
